Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 6Phase 1 6Phase 2/3 2Phase NA 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 35Colorectal Neoplasms 32Neoplasm Metastasis 31Breast Neoplasms 30Prostatic Neoplasms 26Pancreatic Neoplasms 26Ovarian Neoplasms 26Recurrence 25Multiple Myeloma 25Melanoma 23Squamous Cell Carcinoma of Head and Neck 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Triple Negative Breast Neoplasms 17Endometrial Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lung Neoplasms 16Glioblastoma 16Lymphoma, Non-Hodgkin 15Leukemia, Myeloid, Acute 14Burkitt Lymphoma 14Stomach Neoplasms 13Small Cell Lung Carcinoma 12Colonic Neoplasms 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma 11Glioma 11Gastrointestinal Neoplasms 11Lymphoma, Follicular 10

Interventions

zanidatamab 1trastuzumab deruxtecan 1Trastuzumab 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma Of Esophagus × 30 days × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡